Q-omics provides the consensus-scored MUC5AC profile across patient tissues and cancer cell-line models. MUC5AC expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MUC5AC is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, MUC5AC protein abundance shows 11,811 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight UCS, COAD, and UCEC as cancer lineages where MUC5AC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC5AC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC5AC survival associations across molecular data types. MUC5AC RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC5AC RNA expression–survival associations across cancer types. High MUC5AC expression shows unfavorable associations in LUAD, KIRC, ESCA, PAAD and OV, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for MUC5AC RNA expression.
This table summarizes MUC5AC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MUC5AC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC5AC shows higher tumor expression in COAD, UCEC, PAAD, LUAD, BRCA and KIRP. The COAD box plot shows higher MUC5AC RNA expression in tumor versus normal tissue (log2 FC = +1.322, t-test p < 0.001).
This table shows molecular features associated with MUC5AC in patient tissues and cancer cell lines. In patient samples, MUC5AC shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC5AC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and OESOPHAGUS.
